FDA sets review date for Ironshore Pharmaceuticals’ ADHD drug HLD200

Ironshore Pharmaceuticals & Development, a subsidiary of Highland Therapeutics, has reached a significant milestone with the U.S. Food and Drug Administration’s (FDA) acceptance of their ... Read More